publication venue for
- Development of stable amorphous solid dispersion and quantification of crystalline fraction of lopinavir by spectroscopic-chemometric methods. 602:120657-120657. 2021
- 3D-printing of lopinavir printlets by selective laser sintering and quantification of crystalline fraction by XRPD-chemometric models. 592:120059-120059. 2020
- Studying effect of glyceryl palmitostearate amount, manufacturing method and stability on polymorphic transformation and dissolution of rifaximin tablets. 589:119785-119785. 2020
- Controlled curcumin release from nanofibers based on amphiphilic-block segmented polyurethanes. 575:118947-118947. 2020
- Engineered extracellular vesicles with synthetic lipids via membrane fusion to establish efficient gene delivery. 573:118802-118802. 2020
- Evaluation of commercially available meth-deterrent pseudoephedrine hydrochloride products. 575:118909-118909. 2019
- Quantitative evaluation of the thallium binding of soluble and insoluble Prussian blue hexacyanoferrate analogs: A scientific comparison based on their critical quality attributes. 569:118600-118600. 2019
- Blend of cellulose ester and enteric polymers for delayed and enteric coating of core tablets of hydrophilic and hydrophobic drugs. 567:118462-118462. 2019
- Effect of processing parameters and controlled environment storage on the disproportionation and dissolution of extended-release capsule of phenytoin sodium. 550:290-299. 2018
- Quantitative estimation of phenytoin sodium disproportionation in the formulations using vibration spectroscopies and multivariate methodologies. 539:65-74. 2018
- Leachable diphenylguanidine from rubber closures used in pre-filled syringes: A case study to understand solid and solution interactions with oxytocin. 532:491-501. 2017
- Effects of excipients and curing process on the abuse deterrent properties of directly compressed tablets. 517:303-311. 2016
- Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations. 502:138-150. 2016
- Risk based in vitro performance assessment of extended release abuse deterrent formulations. 500:255-267. 2016
- Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations. 499:20-28. 2015
- Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment. 495:783-791. 2015
- Kinetics of drug release from ointments: Role of transient-boundary layer. 494:31-39. 2015
- Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product. 495:19-30. 2015
- Development and validation of X-ray diffraction method for quantitative determination of crystallinity in warfarin sodium products. 493:1-6. 2015
- Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments. 493:412-425. 2015
- Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations. 490:341-350. 2015
- Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin. 481:104-113. 2015
- Cold flow of estradiol transdermal systems: Influence of drug loss on the in vitro flux and drug transfer across human epidermis. 477:73-80. 2014
- Long-term stability study of Prussian blue – A quality assessment of water content and thallium binding. 477:122-127. 2014
- Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics. 475:462-470. 2014
- Development of performance matrix for generic product equivalence of acyclovir topical creams. 475:110-122. 2014
- Root cause evaluation of particulates in the lyophilized indomethacin sodium trihydrate plug for parenteral administration. 473:545-551. 2014
- Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: Iron sucrose. 464:46-52. 2014
- Targeting homeostasis in drug delivery using bioresponsive hydrogel microforms. 461:214-222. 2014
- Challenges of pediatric formulations: A FDA science perspective. 457:346-348. 2013
- Focused beam reflectance measurement to monitor nimodipine precipitation process. 456:353-356. 2013
- Will nanomedicine deliver on its promise of changing therapeutics or remain an interesting and important research tool in cell biology and physiology?. 454:530-531. 2013
- Hunter screening design to understand the product variability of solid dispersion formulation of a peptide antibiotic. 456:572-582. 2013
- Assessing the impact of nimodipine devitrification in the ternary cosolvent system through quality by design approach. 455:113-123. 2013
- Impact of controlled ice nucleation on process performance and quality attributes of a lyophilized monoclonal antibody. 450:70-78. 2013
- Quality by design: Impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody. 438:167-175. 2012
- Application of quality by design to formulation and processing of protein liposomes. 434:349-359. 2012
- Cholorpheniramine tannate complexes: Physicochemical, chemometric, and taste masking evaluation. 436:582-592. 2012
- A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. 426:211-218. 2012
- A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. 423:543-553. 2012
- Predicting hydrophilic drug encapsulation inside unilamellar liposomes. 423:410-418. 2012
- Quality by design approach for formulation development: A case study of dispersible tablets. 423:167-178. 2012
- Crystallinity evaluation of tacrolimus solid dispersions by chemometric analysis. 423:341-350. 2011
- A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. 419:52-59. 2011
- Tannate complexes of antihistaminic drug: Sustained release and taste masking approaches. 422:91-100. 2011
- Quality-by-Design (QbD): An integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and process design space development. 405:63-78. 2011
- In vitro and in vivo evaluation of anti-inflammatory agents using nanoengineered alginate carriers: Towards localized implant inflammation suppression. 403:268-275. 2011
- Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets. 401:25-31. 2010
- Risperidone solid dispersion for orally disintegrating tablet: Its formulation design and non-destructive methods of evaluation. 400:49-58. 2010
- Enhanced gene transfection efficiency by polyamidoamine (PAMAM) dendrimers modified with ornithine residues. 392:294-303. 2010
- Comparative stability of repackaged metoprolol tartrate tablets. 385:92-97. 2010
- Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett–Burman design. 389:186-194. 2009
- Quality-by-Design (QbD): An integrated multivariate approach for the component quantification in powder blends. 372:39-48. 2009
- Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. 370:136-143. 2009
- Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients. 360:77-82. 2008
- Molecular weight determination for colloidal iron by Taguchi optimized validated gel permeation chromatography. 353:21-27. 2008
- Quantitative determination of thallium binding to ferric hexacyanoferrate: Prussian blue. 353:187-194. 2008
- Comparison of the stability of split and intact gabapentin tablets. 350:65-69. 2008
- Process analytical technology (PAT): Effects of instrumental and compositional variables on terahertz spectral data quality to characterize pharmaceutical materials and tablets. 343:148-158. 2007
- Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers. 350:113-121. 2007
- Quality by design: Characterization of self-nano-emulsified drug delivery systems (SNEDDs) using ultrasonic resonator technology. 341:189-194. 2007
- Effect of mean diameter and polydispersity of PLG microspheres on drug release: Experiment and theory. 337:118-126. 2007
- Quality by design: Understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box–Behnken design and desirability function. 332:55-63. 2007
- Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters. 315:110-121. 2006
- Optimization and characterization of controlled release multi-particulate beads coated with starch acetate. 294:89-101. 2005
- Biodisposition of PEG-coated lipid microspheres of indomethacin in arthritic rats. 290:55-62. 2005
- Preparation and in vitro characterization of self-nanoemulsified drug delivery system (SNEDDS) of all-trans-retinol acetate.. 285:109-119. 2004
- Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. 279:3-7. 2004
- Evaluation of cytotoxicity of oils used in coenzyme Q10 Self-Emulsifying Drug Delivery Systems (SEDDS). 273:63-73. 2004
- Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery. 266:51-60. 2003
- Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice. 253:159-168. 2003
- Optimization of a self-nanoemulsified tablet dosage form of Ubiquinone using response surface methodology: effect of formulation ingredients. 240:103-114. 2002
- Optimization and characterization of controlled release multi-particulate beads formulated with a customized cellulose acetate butyrate dispersion. 234:179-193. 2002
- Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. 235:247-265. 2002
- Polymethyacrylate based microparticulates of insulin for oral delivery: Preparation and in vitro dissolution stability in the presence of enzyme inhibitors. 225:31-39. 2001
- Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. 212:233-246. 2001
- Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: evaluation of main effects of several formulation variables. 193:147-156. 2000
- Transbuccal permeation of a nucleoside analog, dideoxycytidine: effects of menthol as a permeation enhancer. 192:139-146. 1999
- Aqueous-based polymeric dispersion: preparation and characterization of cellulose acetate pseudolatex. 165:175-189. 1998
- Optimization and characterization of controlled release pellets coated with an experimental latex: II. Cationic drug. 141:179-195. 1996
- Box-behnken design for the optimization of formulation variables of indomethacin coprecipitates with polymer mixtures. 131:9-17. 1996
- Optimization and characterization of controlled release pellets coated with an experimental latex: I. Anionic drug. 125:243-255. 1995
- Inhibition of granulocyte colony stimulating factor (G-CSF) adsorption to polyvinyl chloride using a nonionic surfactant. 114:177-184. 1995
- Optimization of process variables for the preparation of ibuprofen coprecipitates with eudragit S100. 102:185-192. 1994
- FDA: Contribution to developing pediatric formulations and transatlantic collaboration 2012